Member Info for miavoce

That was my reading Berm i.e. indicates excellent response rate from early iSCIB1+ patients.

Assuming the last of the 32 was a recent recruit - how long till they have their first scan ?

WTP - the panel of experts have presumably seen the early data from the iSCIB1+ patients, so I presume that the RNS is telling us that, having seen this data, the panel of melanoma experts are supportive of progressing the phase 2/3 study i.e. they are confident that it works and should be progressed.

I doubt our buyers are done.

The fact it was explicitly mentioned, together with the make up of the audience, implies it was unusual / relevant.

I'd be surprised if the 500k was a sell - 13.815 was the highest price for a sell today (early morning). Make no odds though, all today's trades are now in the price and as you say, the future is rosy.

I'm guessing that the MM's are going to have to let the prove move up again to get the stock they need to satisfy this buyer. It isn't happening at the current price.

Looks like the tree refused to be shaken. Blue finish ?

It is probably being worked ;-)

If it was a sell C7 they got a very good price for it (10.37) as the spread at the time of the trade was 10 - 10.5.

Today, with 1.5m net buys so far, would be a good opportunity for our seller to offload a large chunk of their remaining stock and hopefully take us a lot closer to seeing the back of them. If they don't sell any today that may mean that they see it going higher in the short term (and so will wait to sell) or they have finished.

The CEO of Redmile has a seat on the Redmile board, but being the CEO of another co. would not give him a seat on Redmile's board. He is however clearly a senior guy, and the right person for the role at Scancell.

Where does it say that Dr. Florian is on the board of Redmile ? Being a Managing Director at Redmile does not mean he is on the board. In a Financial Institution a Managing Director is a senior position but not a board position.

Indeed chester18, Redmile haven't done this on a whim, and nor would they have agreed the CLN extension without some insight into progress. I wonder if, as part of the CLN extension discsussions, Redmile were given some insight into trial progress and as a result they are positioning for the inevitable commercial activity (this would also explain why LD gave the unexpected video interview a few weeks back where she mentioned 'multiple complete responders' - maybe she was subtly putting certain info into the public domain so that she could discuss it in more detail with Redmile).

I concur with the sentiments being expressed. IMO this indicates that we are about to enter a period of significant commercial activity and Redmile now want to be directly involved in order to maximise the benefit for themselves (and therefore all other shareholders).

'My logical thinking tells me - possibly an insider who either is pessimistic about SCLP or desperately in need of some cash to pay the bills' - why on earth would an insider be pessimistic given the outstanding results far. You are IMO very wide of the mark with this negative speculation.

I had similar thoughts when I was the article. Lets hope that it is indeed more than a coincidence.

If you do decide to buy a large volume I would recommend contacting Calculus to see if you can do a bulk buy from them. If you buy a large volume in the market you will end up paying more.

Ruck

my take is that Redmile want Scancell to be able to get the best possible deal for SCIB in H1 2025, and they won't be able to do this if there is fundraise pressure (to pay off the CLN's) hanging over the company.

Harms = pharma's